English

Idogen publishes interim report for 1 January - 31 March 2021

Report this content

Idogen AB's interim report for January to March 2021 is available on the company's website https://idogen.com/en/investors/financial-reports/
 

First quarter (January - March, 2021)

  • Other operating income amounted to KSEK 1,679 (1,414).
  • Operating loss was KSEK -10,651 (-6,634).
  • Loss for the period totaled KSEK -10,531 (-6,220).
  • Cash flow from operating activities was KSEK -9,952 (-1,786).
  • Loss per share before dilution was SEK -0.58 (-1.28) Loss per share after dilution was SEK -0.58 (-1.28).

Significant events in the first quarter

  • Preparations for the application to start clinical trials are progressing well.
  • Documentation and quality assurance of productions processes continues at the partner Radboud University Medical Center.
  • Covid-19 has impact on work at Radboud University Medical Center.
  • The Nomination Committee proposes Lennart Svensson as a new member of the Board.

Significant events after the end of the period

  • Idogen appoints highly reputable scientific advisors in transplantation.
  • The annual report is expanded with Corporate Governance and thus Idogen follows the Idogen Stock Exchange Code.
  • Additional payment, MSEK 3, will be made for the EU project Horizon 2020.
  • No other significant events occurred after the end of the period that affected the results or financial position.

                                                                                                                   

For further information, please contact:

Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com

The information was submitted for publication, through the agency of the contact persons set out above, on May 11, 2021 08:50 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.

Tags:

Interim report Transplantation Medicon Village Idogen cell therapy hemophilia A autoimmune diseases

Subscribe

Documents & Links